0000000000707352

AUTHOR

Fausto Barbieri

showing 3 related works from this author

Supplementary_Material_-_online_only – Supplemental material for Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhi…

2020

Supplemental material, Supplementary_Material_-_online_only for Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG by Melissa Bersanelli, Diana Giannarelli, Ugo De Giorgi, Sandro Pignata, Massimo Di Maio, Elena Verzoni, Alberto Clemente, Valentina Guadalupi, Diego Signorelli, Marcello Tiseo, Raffaele Giusti, Marco Filetti, Marilena Di Napoli, Lorenzo Calvetti, Alessandro Cappetta, Paola Ermacora, Diego Zara, Fausto Barbieri, Cinzia Baldessari, Vieri Scotti, Francesca Mazzoni, Antonello Veccia, Pamela Francesca Guglielmini, Marco Maruzzo, Ernesto Rossi, Francesco Grossi, Chiara Casad…

110203 Respiratory DiseasesFOS: Clinical medicine111702 Aged Health CareFOS: Health sciences111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified111299 Oncology and Carcinogenesis not elsewhere classified
researchProduct

Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors. Prospective analysis from a multicentre observational tri…

2020

Background:This prospective, multicentre, observational INVIDIa-2 study is investigating the clinical efficacy of influenza vaccination in advanced-cancer patients receiving immune-checkpoint inhibitors (ICIs), enrolled in 82 Italian centres, from October 2019 to January 2020. The primary endpoint was the incidence of influenza-like illness (ILI) until 30 April 2020. All the ILI episodes, laboratory tests, complications, hospitalizations and pneumonitis were recorded. Therefore, the study prospectively recorded all the COVID-19 ILI events.Patients and methods:Patients were included in this non-prespecified COVID-19 analysis, if alive on 31 January 2020, when the Italian government declared …

0301 basic medicinemedicine.medical_specialtymedicine.medical_treatmentimmune-checkpoint inhibitorsinfluenza-like illnesslcsh:RC254-28203 medical and health sciences0302 clinical medicineCancer immunotherapyInternal medicineMedicineProspective cohort studyCancer stagingOriginal ResearchInfluenza-like illnessbusiness.industrySARS-CoV-2virus diseasesCOVID-19Immunotherapycancer patients; COVID-19; immune-checkpoint inhibitors; influenza-like illness; SARS-CoV-2lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseComorbidityVaccination030104 developmental biologyOncology030220 oncology & carcinogenesisObservational studybusinesscancer patients
researchProduct

Informal caregiving burden in advanced non-small cell lung cancer: the HABIT study.

2007

Introduction This study's aim was to assess economic data regarding the home assistance burden for advanced non-small cell lung cancer (NSCLC) patients in Italy. Patients and Methods One hundred four NSCLC patients in second-line chemotherapy (2LC) or in supportive therapy (ST) were enrolled in 18 Italian oncology departments and were observed for 3 months. The main caregiver's workload was assessed monthly by a task scale; other caregivers' activities were also registered. Eastern Cooperative Oncology Group performance status was assessed by physicians, and patients completed the Lung Cancer Symptoms (LCS) subscale. Formal caregiving time was valued according to market prices; informal car…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyLung NeoplasmsHome Nursingmedia_common.quotation_subjectAntineoplastic Agentscaregiving burden in advanced non-small cell lung cancerNSCLCQuality of lifeCost of IllnessCarcinoma Non-Small-Cell LungmedicineHumansLung cancermedia_commonAgedAged 80 and overbusiness.industrySocial SupportWorkloadAssistance burdenHealth Care CostsMiddle Agedmedicine.diseaseOncologyCaregiversItalySocioeconomic FactorsInformal caregivingSpouseSupportive psychotherapyScale (social sciences)Family medicinePhysical therapyCosts and Cost AnalysisQuality of LifeFemaleHabitNon small cellbusiness
researchProduct